UVX as an Adjuvant in the Treatment of Fungal Keratitis

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03138785

Enrollment

Registered

2017-05-03

Start date

2015-01-01

Completion date

2017-07-01

Last updated

2017-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment

Brief summary

In this study, investigators want to find the effect of adjuvant collagen cross-linking in the treatment of fungal keratitis

Interventions

DRUGtopical voriconazole / levofloxacin systemic itraconazole

starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks

RADIATIONCXL

30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* fungal keratitis documented by culture or confocal scanning without any previous treatment

Exclusion criteria

* Previous treatment * Thinning at presentation * Perforation * Associated with other microbial or viral keratitis

Design outcomes

Primary

Measure	Time frame	Description
time of complete healing (days)	180 days	time to scar formation (days)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026